Molnuva
Generic Name
Molnupiravir
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| molnuva 200 mg capsule | ৳ 40.00 | ৳ 160.00 |
Description
Overview of the medicine
Molnupiravir is an antiviral medicine used for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Uses & Indications
Dosage
Adults
800 mg (four 200 mg capsules) orally every 12 hours for 5 days. Initiate treatment as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset.
Elderly
No specific dose adjustment is required for elderly patients.
Renal_impairment
No dose adjustment is required for patients with renal impairment.
How to Take
Molnuva capsules should be swallowed whole, with or without food. Do not open, crush, or chew the capsules.
Mechanism of Action
Molnupiravir is a prodrug that is metabolized to the active nucleoside analogue N-hydroxycytidine (NHC). NHC acts by inhibiting SARS-CoV-2 replication through lethal mutagenesis (error catastrophe) of the viral RNA-dependent RNA polymerase.
Pharmacokinetics
Onset
Not specifically defined, but reduction in viral load is observed early in the course of treatment.
Excretion
NHC is primarily eliminated by renal excretion. Approximately 60% of the dose is excreted as NHC in urine.
Half life
The mean elimination half-life of NHC is approximately 3.3 hours.
Absorption
Molnupiravir is rapidly absorbed and extensively converted to the active nucleoside analogue, N-hydroxycytidine (NHC), with peak plasma concentrations occurring approximately 1.5 hours after administration.
Metabolism
Molnupiravir is a prodrug that is rapidly hydrolyzed to NHC by esterases.
Side Effects
Contraindications
- Known hypersensitivity to molnupiravir or any excipients.
- Pregnancy, due to the potential for fetal harm.
Drug Interactions
Limited data
Molnupiravir is not a substrate, inhibitor, or inducer of major drug-metabolizing enzymes (e.g., CYP enzymes) or transporters. Therefore, significant drug-drug interactions are not expected.
Storage
Store in a dry place below 30°C, protected from light and moisture. Keep out of reach of children.
Overdose
There is no specific antidote for molnupiravir overdose. Treatment should consist of general supportive measures, including monitoring of clinical status.
Pregnancy & Lactation
Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential should use effective contraception during treatment and for 4 days after the last dose. Breastfeeding is not recommended during treatment and for 4 days after the last dose; pump and discard breast milk during this period.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the date of manufacture.
Availability
Pharmacies, Hospitals
Approval Status
Emergency Use Authorization (EUA) by FDA, DGDA approved in Bangladesh
Patent Status
Under patent, licensed for generic production in certain regions
Clinical Trials
Efficacy and safety were primarily demonstrated in the MOVe-OUT Phase 3 clinical trial, which enrolled non-hospitalized adult patients with mild to moderate COVID-19 at high risk of progressing to severe disease.
Lab Monitoring
- No specific routine laboratory monitoring is required for patients taking molnupiravir.
Doctor Notes
- Emphasize the importance of early initiation of treatment (within 5 days of symptom onset) for optimal efficacy.
- Ensure robust contraception counseling for women of childbearing potential due to fetal harm risk.
- Molnupiravir is not authorized for pre-exposure or post-exposure prophylaxis for COVID-19, nor for treatment of severe COVID-19 requiring hospitalization.
Patient Guidelines
- Complete the full 5-day course of treatment, even if you start to feel better.
- Do not share this medicine with others, even if they have similar symptoms.
- Contact your doctor immediately if your symptoms worsen or if you experience severe side effects.
- Women of childbearing potential must use effective contraception during treatment and for 4 days after.
Missed Dose Advice
If a dose is missed by more than 10 hours, do not take the missed dose and resume the normal dosing schedule. Do not double the dose to make up for a missed dose.
Driving Precautions
Molnuva is not expected to affect the ability to drive or operate machinery. However, if you experience dizziness, caution is advised.
Lifestyle Advice
- Maintain good hand hygiene and social distancing to prevent further spread of COVID-19.
- Stay well-hydrated and get adequate rest to aid recovery.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.